Business
Zura Bio Reports Business Updates and Outlook for 2026
HENDERSON, Nev., January 12, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported business updates and updated its outlook for 2026.
About this update from Zura Bio Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/38a9b116c2a532ad33f0cd2a7bae97da"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7JhsR1R16fnZXvKekWqt9w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/38a9b116c2a532ad33f0cd2a7bae97da","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/jS7UYZuSLl_63Jb4THtk7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/38a9b116c2a532ad33f0cd2a7bae97da","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"2026 begins as a transformative year for Zura with potential clinical validation of tibulizumab as a groundbreaking therapy in hidradenitis suppurativa (HS)","length":156,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Expanded Phase 2 TibuSHIELD trial in HS expected to deliver topline data in the fourth quarter of 2026","length":102,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Zura maintains a strong financial position with cash expected to fund planned operations through 2027, beyond the data readouts in both HS and systemic sclerosis (SSc)","length":167,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":425,"olType":false},{"type":"text","content":"HENDERSON, Nev., January 12, 2026--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported business updates and updated its outlook for 2026.","length":368,"tagName":"p"},{"type":"text","content":""We are excited to enter 2026, as we get closer to two potentially transformative readouts over the next 18 months for tibulizumab, starting with anticipated data from our TibuSHIELD study in patients with hidradenitis suppurativa in the fourth quarter of this year," said Kim Davis, interim Chief Executive Officer and Chief Operating Officer at Zura. "We believe tibulizumab could be a paradigm shift in addressing the unmet needs of ...